{Reference Type}: Case Reports
{Title}: A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
{Author}: Chen D;Fuda F;Weinberg O;
{Journal}: Int J Lab Hematol
{Volume}: 43
{Issue}: 0
{Year}: Jul 2021
{Factor}: 3.45
{DOI}: 10.1111/ijlh.13565
{Abstract}: Philadelphia (BCR-ABL)-negative myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN can transform into an accelerated or a blast phase, which is associated with poor response to standard therapy and low overall median survival. We present an interesting case of a patient with a history of PMF and progression and summarize the current studies on genetic features of myeloproliferative neoplasms in blast phase (MPN-BP) with an emphasis on PMF. Although MPN-BP show ≥20% blasts in peripheral blood or bone marrow, it is not considered as acute myeloid leukemia (AML) according to the WHO classification. While MPNs-BP typically lack genetic mutations seen in de novo AML, they commonly harbor IDH1/2, SRSF2, ASXL1, and TP53 mutations, similar to the genetic profiles of acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).